FDA警告:透析时谨防代谢性碱中毒

2012-06-13 范振光 医学论坛报

    5月25日,美国食品与药物管理局(FDA)宣布,临床医师在为接受血液透析的患者处方含有醋酸、醋酸盐或柠檬酸盐的透析液时,应注意避免碱剂量误差,因其可导致代谢性碱中毒及死亡风险增加。       上述物质在人体内可被转化为碳酸氢盐,导致代谢性碱中毒。碱水平过高为心跳呼吸骤停、低血压、低钾血症、低氧血症、高碳酸血症和心律不齐的风险因素。

    5月25日,美国食品与药物管理局(FDA)宣布,临床医师在为接受血液透析的患者处方含有醋酸、醋酸盐或柠檬酸盐的透析液时,应注意避免碱剂量误差,因其可导致代谢性碱中毒及死亡风险增加。
 
    上述物质在人体内可被转化为碳酸氢盐,导致代谢性碱中毒。碱水平过高为心跳呼吸骤停、低血压、低钾血症、低氧血症、高碳酸血症和心律不齐的风险因素。
 
    FDA建议临床医师查看透析液标签,以明确有无导致碳酸氢盐水平增加的物质及其含量。须注意,在不同生产厂家和剂型的透析液中,醋酸、醋酸盐或柠檬酸盐水平差异很大(范围为1.5~8 mEq/L)。FDA认为,所有含这些物质的透析产品均存在引发代谢性碱中毒可能。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1970367, encodeId=d96c19e0367cc, content=<a href='/topic/show?id=bf69254332d' target=_blank style='color:#2F92EE;'>#代谢性碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25433, encryptionId=bf69254332d, topicName=代谢性碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Thu Nov 22 01:53:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801389, encodeId=424b1801389d2, content=<a href='/topic/show?id=e887e37075c' target=_blank style='color:#2F92EE;'>#碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73707, encryptionId=e887e37075c, topicName=碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Jan 06 05:53:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989564, encodeId=4edc19895646e, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Nov 30 01:53:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318973, encodeId=730713189e339, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Jun 15 05:53:00 CST 2012, time=2012-06-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1970367, encodeId=d96c19e0367cc, content=<a href='/topic/show?id=bf69254332d' target=_blank style='color:#2F92EE;'>#代谢性碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25433, encryptionId=bf69254332d, topicName=代谢性碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Thu Nov 22 01:53:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801389, encodeId=424b1801389d2, content=<a href='/topic/show?id=e887e37075c' target=_blank style='color:#2F92EE;'>#碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73707, encryptionId=e887e37075c, topicName=碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Jan 06 05:53:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989564, encodeId=4edc19895646e, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Nov 30 01:53:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318973, encodeId=730713189e339, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Jun 15 05:53:00 CST 2012, time=2012-06-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1970367, encodeId=d96c19e0367cc, content=<a href='/topic/show?id=bf69254332d' target=_blank style='color:#2F92EE;'>#代谢性碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25433, encryptionId=bf69254332d, topicName=代谢性碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Thu Nov 22 01:53:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801389, encodeId=424b1801389d2, content=<a href='/topic/show?id=e887e37075c' target=_blank style='color:#2F92EE;'>#碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73707, encryptionId=e887e37075c, topicName=碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Jan 06 05:53:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989564, encodeId=4edc19895646e, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Nov 30 01:53:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318973, encodeId=730713189e339, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Jun 15 05:53:00 CST 2012, time=2012-06-15, status=1, ipAttribution=)]
    2012-11-30 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1970367, encodeId=d96c19e0367cc, content=<a href='/topic/show?id=bf69254332d' target=_blank style='color:#2F92EE;'>#代谢性碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25433, encryptionId=bf69254332d, topicName=代谢性碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Thu Nov 22 01:53:00 CST 2012, time=2012-11-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1801389, encodeId=424b1801389d2, content=<a href='/topic/show?id=e887e37075c' target=_blank style='color:#2F92EE;'>#碱中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73707, encryptionId=e887e37075c, topicName=碱中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4f32220, createdName=lancelotzzl, createdTime=Sun Jan 06 05:53:00 CST 2013, time=2013-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989564, encodeId=4edc19895646e, content=<a href='/topic/show?id=5e202543023' target=_blank style='color:#2F92EE;'>#代谢性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25430, encryptionId=5e202543023, topicName=代谢性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Fri Nov 30 01:53:00 CST 2012, time=2012-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318973, encodeId=730713189e339, content=<a href='/topic/show?id=14d92231508' target=_blank style='color:#2F92EE;'>#中毒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22315, encryptionId=14d92231508, topicName=中毒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Fri Jun 15 05:53:00 CST 2012, time=2012-06-15, status=1, ipAttribution=)]
    2012-06-15 mashirong

相关资讯

华法林治疗和低血浆白蛋白水平是血透患者发生钙化防御的重要危险因素

    钙化防御,也称为钙性尿毒症性小动脉性病,以系统性小血管钙化和组织坏死为特点,是终末期肾病患者的一种致死性少见并发症,西方国家报道长期血透患者的钙化防御的发生率为1-4%。       最近日本学者统计了全国3760个血透中心的数据,其中1838个血透中心得到回复,其中151例个中心报道了共249例钙化防御患者,其中67例纳入研究。 &

血清CysC升高或致MHD者动脉粥样硬化

    最近,上海市闸北区中心医院(长征医院闸北分院)肾内科的研究人员的一项研究显示,血液透析不能有效清除血清胱抑素C(半胱氨酸蛋白酶抑制剂,CysC)等大分子物质,随着透析龄的增加,维持性血液透析(MHD)患者血清CysC水平逐渐升高。CysC与高敏C反应蛋白( hsCRP)等微炎性反应指标及总同型半胱氨酸(tHcy)、颈动脉病变呈正相关,血清CysC水平升高可能是MHD患者

血液透析、注射药物者易反复发生心内膜炎

    意大利米兰市San Raffaele医院的Laura Alagna医生在欧洲临床微生物学与感染性疾病大会上报告,在一项大型国际化前瞻性研究的受试者中发现,血液透析和使用注射药物是反复发生感染性心内膜炎(IE)的重要危险因素。       在初次发生IE后存活的患者中,反复发生IE是一种严重的并发症。以往的研究中,再次发生IE的几率为2%

MHD常并发肺动脉高压

  最近,中国医学科学院北京协和医学院北京协和医院肾内科、心内科的研究人员的一项研究显示,肺动脉高压(PHT)是维持性血液透析(MHD)常见的并发症,其发生与左室收缩和舒张功能下降密切相关;与钙磷代谢、动静脉内瘘(AVF)流量、血红蛋白、透析充分性及营养状态等无明显相关性。该研究发表于2012年第1期《中华肾脏病杂志》。   该研究旨在研究长期维持性血液透析患者PHT的特征及相关因素。

警惕!血液透析引起相关心律失常

解放军总医院老年肾内科 程庆砾           血液透析(HD)相关心律失常是指患者在血液透析治疗开始前无心律失常的病史,而在HD 治疗开始以后出现的心律失常,或在血液透析前已经出现某一种心律失常的基础上又出现了另外一种类型心律失常的临床表现。     发生率    &nbs

CSN:中心静脉导管Palindrome不优于Hemostar

    2012年4月25-29日,加拿大肾脏病学会(CSN)年会在加拿大圣约翰斯召开。会上,加拿大戴尔豪西大学的AlBugami报告的一项研究称,没有证据表明Palindrome中心静脉导管(CVC)较标准的(Hemostar)CVC可延长初次置管通畅时间。     目前,CVC在血液透析中的应用率仍然很高。年龄增长、血管疾病和糖尿病会降低成功建立动静脉瘘(AV